AMIVANTAMAB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 47 adverse event reports in the FDA FAERS database where AMIVANTAMAB was used for Lung neoplasm malignant.
Most Reported Side Effects for AMIVANTAMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Infusion related reaction | 62 | 8.3% | 8 | 26 |
| Rash | 61 | 8.2% | 5 | 26 |
| Pulmonary embolism | 41 | 5.5% | 6 | 28 |
| Dermatitis acneiform | 34 | 4.6% | 2 | 15 |
| Thrombocytopenia | 33 | 4.4% | 4 | 25 |
| Paronychia | 29 | 3.9% | 2 | 13 |
| Diarrhoea | 25 | 3.3% | 8 | 19 |
| Pneumonitis | 24 | 3.2% | 18 | 18 |
| Dyspnoea | 23 | 3.1% | 9 | 13 |
| Nausea | 23 | 3.1% | 5 | 12 |
| Neutropenia | 23 | 3.1% | 1 | 17 |
| Death | 20 | 2.7% | 20 | 9 |
| Deep vein thrombosis | 20 | 2.7% | 1 | 16 |
| Off label use | 20 | 2.7% | 3 | 8 |
| Pneumonia | 20 | 2.7% | 10 | 18 |
Other Indications for AMIVANTAMAB
Non-small cell lung cancer (277)
Non-small cell lung cancer metastatic (213)
Product used for unknown indication (69)
Lung adenocarcinoma (65)
Bronchial carcinoma (12)
Non-small cell lung cancer stage iv (12)
Lung carcinoma cell type unspecified stage iv (11)
Lung adenocarcinoma stage iv (9)
Egfr gene mutation (6)
Metastatic bronchial carcinoma (5)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)